Pharsight

Ixempra Kit patents expiration

IXEMPRA KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125899 R-PHARM US LLC Epothilone derivatives
May, 2018

(6 years ago)

US7125899

(Pediatric)

R-PHARM US LLC Epothilone derivatives
Nov, 2018

(5 years ago)

USRE41911 R-PHARM US LLC Epothilone derivatives
Sep, 2020

(3 years ago)

USRE41911

(Pediatric)

R-PHARM US LLC Epothilone derivatives
Mar, 2021

(3 years ago)

US6670384 R-PHARM US LLC Methods of administering epothilone analogs for the treatment of cancer
Jan, 2022

(2 years ago)

US7022330 R-PHARM US LLC Parenteral formulation for epothilone analogs
Jan, 2022

(2 years ago)

USRE41393 R-PHARM US LLC Treatment of refractory tumors using epothilone derivatives
Feb, 2022

(2 years ago)

US6670384

(Pediatric)

R-PHARM US LLC Methods of administering epothilone analogs for the treatment of cancer
Jul, 2022

(1 year, 10 months ago)

US7022330

(Pediatric)

R-PHARM US LLC Parenteral formulation for epothilone analogs
Jul, 2022

(1 year, 10 months ago)

USRE41393

(Pediatric)

R-PHARM US LLC Treatment of refractory tumors using epothilone derivatives
Aug, 2022

(1 year, 10 months ago)

US7312237 R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Aug, 2024

(2 months from now)

US7312237

(Pediatric)

R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Feb, 2025

(8 months from now)

Ixempra Kit is owned by R-Pharm Us Llc.

Ixempra Kit contains Ixabepilone.

Ixempra Kit has a total of 12 drug patents out of which 10 drug patents have expired.

Expired drug patents of Ixempra Kit are:

  • US7125899
  • US7125899*PED
  • USRE41911
  • USRE41911*PED
  • US6670384
  • US7022330
  • USRE41393
  • US6670384*PED
  • US7022330*PED
  • USRE41393*PED

Ixempra Kit was authorised for market use on 16 October, 2007.

Ixempra Kit is available in injectable;intravenous dosage forms.

Ixempra Kit can be used as a method of treating cancer in a patient comprising administering ixabepilone or pharmaceutical compositions comprising ixabepilone, method of treating breast cancer by administering ixabepilone; a method of treating a cancer responsible to microtubule stabilization by administering ixabepilone, use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer, method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt, method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent.

Drug patent challenges can be filed against Ixempra Kit from 18 April, 2014.

The generics of Ixempra Kit are possible to be released after 21 February, 2025.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 16, 2012
M(M-61) Oct 18, 2014
Pediatric Exclusivity(PED) Apr 18, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using IXABEPILONE ingredient

NCE-1 date: 18 April, 2014

Market Authorisation Date: 16 October, 2007

Treatment: A method of treating cancer in a patient comprising administering ixabepilone or pharmaceutical compositions comprising ixabepilone; Method of treating breast cancer by administering ixabepilone; A me...

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage

IXEMPRA KIT family patents

Family Patents